Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGLENASDAQ:PSTXNASDAQ:SPRONASDAQ:TTPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsPSTXPoseida Therapeutics$9.48$1.87▼$9.67$928.85M1.63882,660 shsN/ASPROSpero Therapeutics$0.58-6.7%$0.79$0.56▼$1.75$32.53M0.64188,807 shs286,902 shsTTPHTetraphase Pharmaceuticals$2.20$2.20$0.56▼$8.60$15.98M2.33932,542 shs282,689 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%PSTXPoseida Therapeutics0.00%0.00%0.00%-0.21%+210.46%SPROSpero Therapeutics0.00%-24.42%-26.14%-47.09%-67.49%TTPHTetraphase Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APSTXPoseida Therapeutics1.2507 of 5 stars3.00.00.04.60.00.80.0SPROSpero Therapeutics4.0717 of 5 stars3.33.00.04.70.60.82.5TTPHTetraphase PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics 0.00N/AN/AN/APSTXPoseida Therapeutics 2.00Hold$9.50∞ UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00759.11% UpsideTTPHTetraphase Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPRO, AGLE, TTPH, and PSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/30/2025SPROSpero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 4/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00PSTXPoseida Therapeutics$150.86M0.00N/AN/A$1.08 per share0.00SPROSpero Therapeutics$27.40M1.19$0.36 per share1.62$2.02 per share0.29TTPHTetraphase Pharmaceuticals$7.38M2.17N/AN/A$6.68 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/APSTXPoseida Therapeutics-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/ASPROSpero Therapeutics$22.81M-$1.278.32N/AN/A3.30%4.03%2.21%5/13/2025 (Estimated)TTPHTetraphase Pharmaceuticals-$70.08M-$22.85N/AN/AN/A-798.18%-210.86%-121.73%N/ALatest SPRO, AGLE, TTPH, and PSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024SPROSpero Therapeutics-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/APSTXPoseida TherapeuticsN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.0610.31%N/AN/A N/ATTPHTetraphase PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59PSTXPoseida Therapeutics0.683.203.20SPROSpero TherapeuticsN/A2.682.68TTPHTetraphase Pharmaceuticals0.063.663.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/APSTXPoseida Therapeutics46.87%SPROSpero Therapeutics25.60%TTPHTetraphase Pharmaceuticals42.29%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%PSTXPoseida Therapeutics2.90%SPROSpero Therapeutics4.52%TTPHTetraphase Pharmaceuticals5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionablePSTXPoseida Therapeutics26097.77 million94.94 millionOptionableSPROSpero Therapeutics15055.90 million52.05 millionOptionableTTPHTetraphase Pharmaceuticals1197.26 millionN/AOptionableSPRO, AGLE, TTPH, and PSTX HeadlinesRecent News About These CompaniesNAFDAC Seeks More Synergy with Indian Pharmaceutical SectorMarch 12, 2023 | thisdaylive.comInfinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News SummaryFebruary 26, 2023 | benzinga.comTetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test ResultsAugust 30, 2022 | thestreet.comTetraphase Executive Profits Hours Before Stock PlummetsAugust 20, 2022 | thestreet.comTTPH_old Historical DataApril 4, 2022 | investing.com10 Worst NASDAQ Biotech Stocks in the Third QuarterJanuary 16, 2022 | thestreet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRO, AGLE, TTPH, and PSTX Company DescriptionsAeglea BioTherapeutics NASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Poseida Therapeutics NASDAQ:PSTXPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Spero Therapeutics NASDAQ:SPRO$0.58 -0.04 (-6.73%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+3.44%) As of 04/4/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Tetraphase Pharmaceuticals NASDAQ:TTPHTetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Advance Auto Parts Stock: A Classic Rebound Play in the Making Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
